Purchases and Sales Made in Q4 2022 in Keros Therapeutics, Inc. (KROS)
This table provides information about the institutional ownership of Keros Therapeutics, Inc. (KROS) during Q4 2022. The information is specifically focused on institutions that hold shares of Keros Therapeutics, Inc..
| Report Date | Institution (Fund) | Operation | Option | Shares change | Value Range | Shares Held | Trade History |
|---|---|---|---|---|---|---|---|
|
Feb 13, 2023
Q4 2022
|
Goldman Sachs Group Inc
New York, NY |
SELL
|
- |
-30.5K- 17.32% |
$1.2M - $1.58M
|
146K
$2.31M
|
|
|
May 14, 2024
Q4 2022
|
Goldman Sachs Group Inc
New York, NY |
SELL
|
- |
-30.5K- 17.32% |
$1.2M - $1.58M
|
146K
$2.31M
|
|
|
Feb 14, 2023
Q4 2022
|
Sphera Funds Management Ltd.
Tel Aviv, L3 |
SELL
|
- |
-48.1K- 23.24% |
$1.9M - $2.49M
|
159K
$2.51M
|
|
|
Feb 14, 2023
Q4 2022
|
Nantahala Capital Management, LLC
New Canaan, CT |
SELL
|
- |
-53.6K- 6.34% |
$2.11M - $2.77M
|
792K
$12.5M
|
|
|
Feb 13, 2023
Q4 2022
|
Cibc Asset Management Inc
Toronto, A6 |
SELL
|
- |
-56.2K- 38.41% |
$2.22M - $2.91M
|
90.1K
$1.43M
|
|
|
Feb 13, 2023
Q4 2022
|
Barclays PLC
London, X0 |
SELL
|
- |
-59.6K- 61.12% |
$2.35M - $3.09M
|
37.9K
$601K
|
|
|
Feb 09, 2023
Q4 2022
|
Citigroup Inc
|
SELL
|
- |
-64K- 13.45% |
$2.53M - $3.31M
|
412K
$6.53M
|
|
|
Feb 10, 2023
Q4 2022
|
Opaleye Management Inc.
Boston, MA |
SELL
|
- |
-83.3K- 25.93% |
$3.29M - $4.31M
|
238K
$3.77M
|
|
|
Feb 08, 2023
Q4 2022
|
Ubs Group Ag
|
SELL
|
- |
-114K- 69.87% |
$4.5M - $5.9M
|
49.2K
$779K
|
|
|
Feb 14, 2023
Q4 2022
|
Woodline Partners LP
San Francisco, CA |
SELL
|
- |
-146K- 42.57% |
$5.75M - $7.55M
|
197K
$3.12M
|